Satralizumab |
| Catalog No.GC66342 |
Satralizumab, un anticuerpo monoclonal humanizado, es un potente inhibidor de la interleucina-6 (IL-6). Satralizumab previene la formaciÓn y progresiÓn de dTAA en rattus norvegicus. Satralizumab se puede utilizar para la investigaciÓn del trastorno del espectro de la neuromielitis Óptica (NMOSD) y el aneurisma de la aorta torÁcica descendente (dTAA).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1535963-91-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].
Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus[1].
| Animal Model: | Rattus norvegicus (forty, male, 10-week-old, four equal groups)[1] |
| Dosage: | 120 mg |
| Administration: | Subcutaneously, once every 2 weeks, for 4 weeks |
| Result: | Prevented dTAA (descending thoracic aorta aneurysm) formation and progression. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *